GlassScriptPhysician profile
Jonathan Heckart
NPI 1073004156
$2,078.37
in general payments reported to CMS, 2019-2025
28 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.19 · 2020: $59.83 · 2021: $96.03 · 2023: $85.82 · 2024: $690 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821 · Education: $60.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.20 |
| Education | $60.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $366.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $225.78 | 2024-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $181.28 | 2024-2025 | Freestyle Libre 3 |
| Insulet Corporation | $167.55 | 2024-2025 | Omnipod |
| Sequel Med Tech, LLC | $111.08 | 2025 | Twiist |
| Lilly USA, LLC | $97.47 | 2024 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $95.43 | 2020-2021 | |
| Medtronic, INC. | $89.56 | 2024-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.20 | 2019-2025 | Jardiance |
| Dexcom, INC. | $83.13 | 2024-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $77.34 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Rhythm Pharmaceuticals, INC. | $74.43 | 2024-2025 | Imcivree |
| Horizon Therapeutics Plc | $71.06 | 2023 | Tepezza |
| Corcept Therapeutics | $51.45 | 2023-2025 | Korlym |
| Mannkind Corporation | $37.90 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28.16 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $25.57 | 2025 | Yorvipath |
| Ascensia Diabetes Care US INC. | $23.52 | 2025 | |
| Xeris Pharmaceuticals, INC. | $23.00 | 2024 | Gvoke Hypopen |
| Abbvie INC. | $21.74 | 2024 | |
| Kyowa Kirin, INC. | $19.71 | 2025 | |
| Allergan, INC. | $18.30 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $17.31 | 2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $17.11 | 2025 | Strensiq |
| Recordati_rare_diseases_inc. | $17.10 | 2025 | Signifor Lar |
| Sandoz INC. | $16.95 | 2025 | Jubbonti |
| Antares Pharma, INC. | $15.94 | 2025 | Xyosted |
| Neurocrine Biosciences, INC. | $15.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Heckart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.